Agoosto 22, 2025, Datopotamab deruxtecan (Dato-DXd; Datroway) waxay heshay oggolaansho Shiinaha si loogu daaweeyo bukaanada qaangaarka ah ee qaba kansarka naasaha ee aan la tirtiri karin ama aan la daaweyn karin -- positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, ama IHC 2+/in situ hybridization [ISH] negative) kuwaas oo hore u helay daaweynta endocrine iyo ugu yaraan 1 khad oo kiimoterabiga ah oo ku jira xaalad horumarsan.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Oggolaanshahani wuxuu ku salaysan yahay natiijooyinka togan ee daraasadda caalamiga ah ee Wejiga III TROPION-Breast01. Daraasadda caalamiga ah ee marxaladda 3aad, calaamad furan, ee TROPION-Breast01 oo la kala soocay ayaa qiimaysay antigen-ka dusha sare ee unugyada trophoblast ee 2-tilmaansan ee antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) iyo doorashada baaraha ee kiimoterabiga (ICC) ee soo-dhoweeyaha hoormoonka-soo-dhoweeyaha koritaanka epidermal-ka ee togan/human epidermal-ka 2-taban (HR+/HER2-) kansarka naasaha.
Bukaannada waxaa si aan kala sooc lahayn loogu qoondeeyay Dato-DXd (n = 365) ama ICC (n = 367). Dato-DXd si weyn ayuu u yareeyay khatarta horumarka ama dhimashada marka loo eego ICC (PFS marka loo eego saamiga khatarta BICR [HR], 0.63 [95% CI, 0.52 ilaa 0.76]; P < .0001). Faa'iidada PFS ee joogtada ah ayaa lagu arkay kooxo hoosaadyo ah. Inkasta oo xogta OS aysan bislaan, isbeddel u janjeera Dato-DXd ayaa la arkay (HR, 0.84 [95% CI, 0.62 ilaa 1.14]). Heerka dhacdooyinka xun ee la xiriira daaweynta ee heerka ≥3 (TRAEs) ee leh Dato-DXd wuxuu ka hooseeyay ICC (20.8% v 44.7%). TRAE-yada ugu badan (darajada kasta; darajada ≥3) waxay ahaayeen lallabbo (51.1%; 1.4%) iyo stomatitis (50%; 6.4%) oo leh Dato-DXd iyo neutropenia (erey kooxeed, 42.5%; 30.8%) oo leh ICC.
Bukaannada qaata Dato-DXd waxay lahaayeen horumar tirakoob ahaan muhiim ah oo macno leh oo ku yimid PFS iyo astaan badbaado oo wanaagsan oo la maareyn karo, marka la barbar dhigo ICC.
Waqtigan xaadirka ah, waxaa weli jira tijaabooyin caafimaad oo badan oo ku saabsan teknoolojiyada cusub ee ka hortagga kansarka ee Shiinaha oo raadinaya bukaanno. La-tashi ku saabsan daawooyinka cusub iyo teknoolojiyada, waxaad la xiriiri kartaa Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing.
Lambarka Taleefanka: 4008803716
Aqoonsiga WeChat: 17801183037
Email：myimmnet@163.com
Waqtiga boostada: Agoosto-26-2025